ASH Highlights

In patients with newly diagnosed multiple myeloma (NDMM), the use of anti-CD38 monoclonal antibodies (mAbs) enhances the effectiveness of standard treatment protocols, according to a study presented at the 66thAmerican Society of Hematology Annual Meeting & Exposition in San Diego, CA. Read More ›

Adding tafasitamab (Monjuvi; Incyte) to lenalidomide (Revlimid) and rituximab (Rituxan) resulted in a 57% reduction in investigator-assessed risk of progression, relapse, or mortality in patients with relapsed or refractory follicular lymphoma, according to results from the inMIND trial, which were presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA. Read More ›

Daratumumab (Darzalex Faspro; Johnson & Johnson) use was associated with a 51% reduction in risk of disease progression for patients with smoldering multiple myeloma, when compared with similar patients who were actively monitored but not treated, according to results of a study presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA. Read More ›

Merck’s investigational antibody–drug conjugate that targets receptor tyrosine kinase–like orphan receptor 1 (ROR1), zilovertamab vedotin, used in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) achieved a 100% (n=15) complete response (CR) rate, according to results presented at the 66th ASH Annual Meeting and Exposition, in San Diego, CA, and simultaneously published in Blood. Read More ›

Using cannabis to reduce pain associated with their cancer would be “highly” accepted among patients with multiple myeloma (MM), but more education is needed for oncology providers in discussing its use with these patients, according to results of a survey presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA Read More ›

The financial burden often accompanying a cancer diagnosis, coupled with consequent unmet health-related social needs like food insecurity (FI), may be associated with increased trips to the emergency department (ED). Ongoing screening of these patients to help identify areas to intervene and, perhaps, reduce these trips is warranted. Read More ›

The first responders who were exposed to high levels of airborne dust, gases, and potential cancer-causing substances at Ground Zero following the 9/11 attacks that destroyed the Twin Towers in New York may now be facing an increased risk of developing leukemia and exhibit a distinct spectrum of precancerous genetic changes, according to data presented at the 66th ASH Annual Meeting and Exposition held in San Diego, CA. Read More ›

Subgroup analyses presented at the American Society of Hematology (ASH) Annual Meeting San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Read More ›

San Diego—Ibrutinib plus venetoclax significantly improved progression-free (PFS) and overall survival (OS) compared with a standard fludarabine, cyclophosphamide, and rituximab (FCR) regimen in patients with untreated chronic lymphocytic leukemia (CLL) and now represents a new standard for treatment of the disease. Read More ›

San Diego—In the first randomized trial conducted in patients with myelofibrosis who have not previously been treated with a JAK inhibitor, twice as many who received an investigational targeted agent (navitoclax) in addition to a JAK inhibitor had a clinically significant reduction in spleen size compared with those who received JAK inhibitor monotherapy. Read More ›